Harmony Biosciences Holdings (HRMY) said Monday it expects Q4 net product revenue of $201 million.
Analysts polled by FactSet expect $198.6 million.
The company reported preliminary 2024 net product revenue for the year ended Dec. 31 of $714 million, falling within its guidance for $700 million to $720 million.
Analysts surveyed by FactSet expect $712.1 million.
Harmony said it expects 2025 net product revenue of between $820 and $860 million. Analysts polled by FactSet expect $847.3 million.
Shares of the company were up more than 6% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。